The obesity-related pharmaceutical market in Saudi Arabia is witnessing rapid growth, fueled by high obesity rates and the increasing demand for effective medical treatments. Here’s a breakdown of the latest insights and projections.
Market Size and Growth Outlook
Weight Loss Drugs Market
Saudi Arabia’s weight loss drugs sector is expanding at an impressive pace. In 2023, the market was valued at approximately USD 1.92 billion, and it is expected to skyrocket to USD 45.35 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 43.73% from 2024 to 2032.
Obesity Treatment Market
In 2024, the broader obesity treatment market, including medications, generated USD 52.1 million in revenue. This figure is forecasted to reach USD 140.7 million by 2030, with a CAGR of 16.6% between 2025 and 2030.
This growth is primarily driven by the rising prevalence of obesity, which has created a strong demand for pharmaceutical solutions.
Usage Trends in the Kingdom
A recent study on primary healthcare centers in Jeddah showed a snapshot on all drug classes:
– Ozempic was the most commonly used anti-obesity drug (13% usage rate)
– Mounjaro followed with 6.6%
– Saxenda came in at 6.4%
Top Drug Categories in the Market
GLP-1 Receptor Agonists
Within the GLP-1 class only, (Semaglutide) dominates the market:
– Wegovy (Semaglutide) held the largest market share (83.19%) in 2024
– Zepbound (Tirzepatide) is the fastest-growing drug segment
– Saxenda (Liraglutide) is also widely used and contributes significantly to overall revenue
Appetite Suppressants
Short-term prescription options such as:
– Phentermine (Zantryl)
– Diethylpropion (Amfepramone)
SGLT-2 Inhibitors
Originally developed for diabetes management, these medications also support weight loss:
– Canagliflozin (Invokana)
– Dapagliflozin (Forxiga)
Combination Medications
For example:
– Qsymia combines an appetite suppressant with another agent to enhance weight loss outcomes.
Conclusion
The obesity-related pharmaceutical market in Saudi Arabia is growing rapidly, backed by strong demand, effective medications, and national health goals under Vision 2030. With billions of dollars in projected revenue and continued innovation in drug development, Saudi Arabia is set to become a regional leader in obesity treatment.